Home > Research > Publications & Outputs > Do funding agencies select and enable novel res...

Electronic data

  • w30320

    Accepted author manuscript, 1.1 MB, PDF document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License

Links

View graph of relations

Do funding agencies select and enable novel research: evidence from ERC

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Do funding agencies select and enable novel research: evidence from ERC. / Veugelers, Reinhilde; Wang, Jian; Stephan, Paula.
In: Economics of Innovation and New Technology, 03.04.2025, p. 1-18.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Veugelers R, Wang J, Stephan P. Do funding agencies select and enable novel research: evidence from ERC. Economics of Innovation and New Technology. 2025 Apr 3;1-18.

Author

Veugelers, Reinhilde ; Wang, Jian ; Stephan, Paula. / Do funding agencies select and enable novel research : evidence from ERC. In: Economics of Innovation and New Technology. 2025 ; pp. 1-18.

Bibtex

@article{32315755f8404c1dbae1e5ecd5a7a5a8,
title = "Do funding agencies select and enable novel research: evidence from ERC",
abstract = "Concern exists that public funding of science is insufficiently supportive of pioneering research that has the potential for generating the future breakthroughs. Funders have addressed this concern by launching specially designed programs. The European Commission established in 2007 the European Research Council (ERC) to support {\textquoteleft}high-risk/high-gain pioneering{\textquoteright} research. This paper sets out to study whether the ERC selected researchers with a track record of conducting highly novel research. We measure novelty in the publication records of applicants before and after the application. Our analysis shows that applicants with a history of highly novel research are less likely to be selected for funding than those without such a history, especially for early career applicants, and if they are located in non-top host environments. This selection penalty for novelty also holds among those applicants with a history of excellent publications. Testing whether receiving a long and generous prestigious ERC grant promotes the production of highly novel research, we only find for early career grantees a significant positive novelty treatment effect. This positive treatment effect is in part due to unsuccessful applicants cutting back on highly novel research. We cautiously interpret this as a {\textquoteleft}lesson learned{\textquoteright} that novelty is not rewarded.",
keywords = "science funding, selection, treatment, novel research, ERC",
author = "Reinhilde Veugelers and Jian Wang and Paula Stephan",
year = "2025",
month = apr,
day = "3",
language = "English",
pages = "1--18",
journal = "Economics of Innovation and New Technology",
issn = "1043-8599",
publisher = "Routledge",

}

RIS

TY - JOUR

T1 - Do funding agencies select and enable novel research

T2 - evidence from ERC

AU - Veugelers, Reinhilde

AU - Wang, Jian

AU - Stephan, Paula

PY - 2025/4/3

Y1 - 2025/4/3

N2 - Concern exists that public funding of science is insufficiently supportive of pioneering research that has the potential for generating the future breakthroughs. Funders have addressed this concern by launching specially designed programs. The European Commission established in 2007 the European Research Council (ERC) to support ‘high-risk/high-gain pioneering’ research. This paper sets out to study whether the ERC selected researchers with a track record of conducting highly novel research. We measure novelty in the publication records of applicants before and after the application. Our analysis shows that applicants with a history of highly novel research are less likely to be selected for funding than those without such a history, especially for early career applicants, and if they are located in non-top host environments. This selection penalty for novelty also holds among those applicants with a history of excellent publications. Testing whether receiving a long and generous prestigious ERC grant promotes the production of highly novel research, we only find for early career grantees a significant positive novelty treatment effect. This positive treatment effect is in part due to unsuccessful applicants cutting back on highly novel research. We cautiously interpret this as a ‘lesson learned’ that novelty is not rewarded.

AB - Concern exists that public funding of science is insufficiently supportive of pioneering research that has the potential for generating the future breakthroughs. Funders have addressed this concern by launching specially designed programs. The European Commission established in 2007 the European Research Council (ERC) to support ‘high-risk/high-gain pioneering’ research. This paper sets out to study whether the ERC selected researchers with a track record of conducting highly novel research. We measure novelty in the publication records of applicants before and after the application. Our analysis shows that applicants with a history of highly novel research are less likely to be selected for funding than those without such a history, especially for early career applicants, and if they are located in non-top host environments. This selection penalty for novelty also holds among those applicants with a history of excellent publications. Testing whether receiving a long and generous prestigious ERC grant promotes the production of highly novel research, we only find for early career grantees a significant positive novelty treatment effect. This positive treatment effect is in part due to unsuccessful applicants cutting back on highly novel research. We cautiously interpret this as a ‘lesson learned’ that novelty is not rewarded.

KW - science funding

KW - selection

KW - treatment

KW - novel research

KW - ERC

M3 - Journal article

SP - 1

EP - 18

JO - Economics of Innovation and New Technology

JF - Economics of Innovation and New Technology

SN - 1043-8599

ER -